The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine

Background: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. Materials and Methods: This is a cost-effectiveness analysis performed as a cr...

Full description

Bibliographic Details
Main Authors: Javad Javan-Noughabi, Aziz Rezapour, Aziz Kassani, Nahid Hatam, Niloofar Ahmadloo
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Journal of Research in Medical Sciences
Subjects:
Breast neoplasms
cost-benefit analysis
cyclophosphamide
doxorubicin
paclitaxel
Online Access:http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2018;volume=23;issue=1;spage=57;epage=57;aulast=Javan-Noughabi

Similar Items

Similar Items